Biosimilar Newsletter Archive

81. 11.22.23 -- Preformulation Of Excipients In Biologics Development 11/22/2023
    11/22/23 Biosimilar Development Newsletter
82. 11.16.23 -- Understanding The FDA's Current Focus On REMS 11/16/2023
    11/16/23 Biosimilar Development Newsletter
83. 11.13.23 -- Strategies To Industrialize Lentivirus And AAV Processes 11/13/2023

    11/13/23 Biosimilar Development Newsletter

84. 11.09.23 -- Strategies For mAb And mAb Variant Chromatography Process Development 11/9/2023

    11/09/23 Biosimilar Development Newsletter

85. 11.09.23 -- Legal & IP Protection For New Biotechs 11/9/2023
    11/09/23 Biosimilar Development Newsletter
86. 11.06.23 -- Design A Successful Viral Clearance Study For Your Biologic 11/6/2023

    11/06/23 Biosimilar Development Newsletter

87. 11.02.23 -- FDA Updates Labeling Recommendations For Biosimilar Products 11/2/2023
    11/02/23 Biosimilar Development Newsletter
88. 10.26.23 -- 5 Best Practices For Responding To FDA Form 483 Inspection Observations 10/26/2023
    10/26/23 Biosimilar Development Newsletter
89. 10.25.23 -- Key Considerations For Aseptic Filling 10/25/2023

    10/25/23 Biosimilar Development Newsletter

90. 10.19.23 -- FDA Grants Interchangeable Designation To Pfizer's Biosimilar ABRILADA 10/19/2023
    10/19/23 Biosimilar Development Newsletter